This House of Lords Library Briefing provides information on recent developments surrounding cannabis use for medicinal purposes.
Medical Cannabis: Recent Developments (289 KB , PDF)
According to the NHS, medical cannabis, also known as medicinal cannabis, is “a broad term for any sort of cannabis-based medicine used to relieve symptoms”. The cannabis plant contains more than a hundred different chemical compounds called cannabinoids, some of which are the active ingredients in prescription medicines. The most well-known cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD).
Under the Misuse of Drugs Act 1971, cannabis (as well as most cannabinoids) is a controlled drug. Prior to September 2018, cannabis-based medicinal products could only be accessed through the granting of an individual licence. Following a review by the Chief Medical Officer and the Advisory Council on the Misuse of Drugs, the Home Office announced that from 1 November 2018 cannabis-based medicinal products would be rescheduled under the relevant regulations, meaning they could be prescribed by doctors on the Specialist Register of the General Medical Council.
Cannabis use for medicinal purposes is allowed in several countries and territories across the world. These include the Netherlands, Canada, France, Germany and some US states. In the Netherlands, for example, cannabis for medicinal purposes is available with a physician’s prescription and can be prescribed by all doctors.
In December 2018, the House of Commons Health and Social Care Committee launched an inquiry into issues around medicinal cannabis. The committee stated that while the rescheduling of cannabis for medicinal purposes had been “widely welcomed”, there had been a “failure” to communicate what this would mean “in practice”. In September 2019, the Government responded to the recommendations set out in the committee’s report. These included providing clearer information on availability and building the evidence base.
New National Institute for Health and Care Excellence (NICE) guidelines were published in November 2019 on the prescribing of cannabis-based products. The guidance recommends specific cannabis-based products in the treatment of intractable nausea and vomiting and for spasticity in Multiple Sclerosis (MS), but not for the treatment of pain. The guidelines did not recommend these products for severe treatment-resistant epilepsy, however NICE made research recommendations in this area.
Medical Cannabis: Recent Developments (289 KB , PDF)
In October 2024, a report from the House of Lords Food, Diet and Obesity Committee concluded that poor-quality diets were contributing to an obesity crisis in England. It said that successive governments had failed to tackle the issue, and more regulation was now needed. This briefing summarises the committee’s recommendations, the government’s response in January 2025, and reaction to both reports.
On 9 March, the Covid-19 Day of Reflection 2025 took place to mark five years since the start of the pandemic in the UK. This briefing has been prepared ahead of a debate in the House of Lords focused on the support available to those bereaved because of Covid-19. It outlines the help available for families and sets out background information on the Covid-19 Day of Reflection, as well as the UK Covid-19 inquiry.
On 6 March 2025, the House of Lords is scheduled to hold a debate marking International Women’s Day focused on the steps being taken to promote women’s participation and leadership in science and technology. The motion for the debate is sponsored by Baroness Gustafsson, the government minister for investment. This briefing provides an overview of data and research in this area, as well as information on government policy.
